WHAT IS CLAIMED IS:

1. Use of an anti-IL-6 antibody in the manufacture of a medicament for treating left ventricular heart failure, wherein a therapeutically effective amount of the medicament is to be administered to a patient with left ventricular heart failure.

2. The use of claim 1, wherein the patient has elevated pre-treatment plasma IL-6 levels.

3. The use of claim 2, wherein the patient has a pre-treatment plasma IL-6 level of greater than 2 pg/mL.

4. The use of claim 1, wherein the patient has a diuretic efficiency of less than 500 mmol Na/doubling of loop diuretic dose.

5. The use of claim 4, wherein the patient has a diuretic efficiency of less than 200 mmol Na/doubling of loop diuretic dose.

6. The use of claim 5, wherein the patient has diuretic resistant heart failure.

7. The use of claim 1, wherein the patient has acute heart failure.

8. The use of claim 1, wherein the patient has chronic heart failure.

9. The use of claim 1, wherein the anti-IL-6 antibody comprises all six variable region CDRs of MEDI5117 and wherein MEDI5117 has the following CDR and heavy and light chain sequences:
(a) a VH CDR1 having the amino acid sequence of SEQ ID NO: 9;
(b) a VH CDR2 having the amino acid sequence of SEQ ID NO: 10;
(c) a VH CDR3 having the amino acid sequence of SEQ ID NO: 11;
(d) a VL CDR1 having the amino acid sequence of SEQ ID NO: 12;
(e) a VL CDR2 having the amino acid sequence of SEQ ID NO: 13;
(f) a VL CDR3 having the amino acid sequence of SEQ ID NO: 14.
(g) a heavy chain having the amino acid sequence of SEQ ID NO: 15; and
(h) a light chain having the amino acid sequence of SEQ ID NO: 16.

10. The use of claim 9, wherein the antibody comprises the VH and VL of MEDI5117.

11. The use of claim 10, wherein the antibody is MEDI5117.

12. The use of claim 1, wherein the anti-IL-6 antibody is MEDI5117 and wherein MEDI5117 has the following CDR and heavy and light chain sequences:
(a) a VH CDR1 having the amino acid sequence of SEQ ID NO: 9;
(b) a VH CDR2 having the amino acid sequence of SEQ ID NO: 10;
(c) a VH CDR3 having the amino acid sequence of SEQ ID NO: 11;
(d) a VL CDR1 having the amino acid sequence of SEQ ID NO: 12;
(e) a VL CDR2 having the amino acid sequence of SEQ ID NO: 13;
(f) a VL CDR3 having the amino acid sequence of SEQ ID NO: 14.
(g) a heavy chain having the amino acid sequence of SEQ ID NO: 15; and
(h) a light chain having the amino acid sequence of SEQ ID NO: 16; and wherein the anti-IL-6 antibody is to be administered subcutaneously in a flat dose of from 10 - 20 mg.